Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 55, Issue 6, Pages 2992-2994Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01696-10
Keywords
-
Categories
Funding
- University of Manitoba
- National Microbiology Laboratory
- AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom
Ask authors/readers for more resources
The in vitro activity of ceftazidime in combination with NXL104 versus 470 Pseudomonas aeruginosa clinical isolates was evaluated using Clinical and Laboratory Standards Institute (CLSI) broth microdilution methods. Ceftazidime had MIC(90)s of 8 mu g/ml and 32 mu g/ml in the presence and absence of NXL104, respectively. Of 25 multidrug-resistant P. aeruginosa isolates, the percentages with a ceftazidime MIC of <= 8 mu g/ml with and without NXL104 were 60% and 4%, respectively. These data suggest that the ceftazidime-NXL104 combination may prove useful for treating many P. aeruginosa infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available